Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for F. Hoffmann-La Roche AG
-0.30 (-2.45%)
After Hours: 11.96 0.00 (0.00%)
Apr 23, 5:16PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.76 - 12.35
52 week 8.72 - 15.34
Open 12.24
Vol / Avg. 1.01M/1.41M
Mkt cap 1.51B
P/E     -
Div/yield     -
EPS -1.40
Shares 126.65M
Beta 1.32
Inst. own 86%
Jun 9, 2014
NEKTAR THERAPEUTICS Annual Shareholder Meeting (Estimated) Add to calendar
May 5, 2014
Q1 2014 NEKTAR THERAPEUTICS Earnings Release (Estimated) Add to calendar
Apr 8, 2014
NEKTAR THERAPEUTICS at Needham Healthcare Conference
Mar 10, 2014
Mar 5, 2014
NEKTAR THERAPEUTICS at Cowen Health Care Conference
Feb 26, 2014
Q4 2013 NEKTAR THERAPEUTICS Earnings Conference Call
Feb 26, 2014
Q4 2013 NEKTAR THERAPEUTICS Earnings Release
Feb 13, 2014
NEKTAR THERAPEUTICS at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -153.02% -108.79%
Operating margin -115.24% -80.67%
EBITD margin - -71.08%
Return on average assets -46.76% -34.75%
Return on average equity - -
Employees 445 -
CDP Score - -


455 Mission Bay Boulevard South
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is consisted of early to late stage drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve both small molecule and biologic drug candidates. It creates drug candidates by using its advanced polymer conjugate technologies to modify the chemical structure of pharmacophores to create new molecular entities. Its drug candidate, naloxegol (formerly known as NKTR-118), is an oral opioid antagonist, which has completed Phase III clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain. Its second drug candidate, etirinotecan pegol (also known as NKTR-102), is a topoisomerase I inhibitor, which is under Phase III clinical study as of December 31, 2012.

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
John Nicholson Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 47
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Gil Labrucherie J.D Senior Vice President, General Counsel, Secretary
Age: 41
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 59
Bio & Compensation  - Reuters
Robert A. Medve M.D. Senior Vice President, Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 54
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 61
Bio & Compensation  - Reuters